Cencora, Inc. vs Unilever PLC: Strategic Comparison

This in-depth comparison examines Cencora, Inc. and Unilever PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cencora, Inc. on its own, evaluating Unilever PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cencora, Inc. and Unilever PLC is widest.

On the headline numbers, Cencora, Inc. reports annual revenue of $321.3B against $54.9B for Unilever PLC, while their respective market capitalizations stand at $50.0B and $151.9B. Cencora, Inc. is headquartered in United States and Unilever PLC operates from United Kingdom, and those different home markets shape how each company competes.

Cencora, Inc.: Cencora buys and distributes pharmaceuticals, specialty drugs, animal health products, and related healthcare supplies while also providing commercialization, logistics, and provider services through U.S. and international platforms.

Unilever PLC: Unilever used to be described by breadth: hundreds of brands, many categories, many countries. The current strategy is the opposite: fewer brands, clearer ownership, more disciplined capital allocation, and a portfolio tilted toward higher-growth personal care and beauty.

Cencora, Inc. and Unilever PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cencora, Inc. and Unilever PLC.

Cencora, Inc. business model: Cencora makes money primarily through high-volume pharmaceutical wholesale distribution. It also earns revenue from specialty distribution, provider services, international distribution, biopharma logistics, commercialization services, and animal-health distribution.

Unilever PLC business model: Unilever makes money by building and distributing branded consumer products through supermarkets, drugstores, convenience channels, emerging-market distributors, e-commerce, foodservice, and direct or prestige beauty channels. Scale in procurement, manufacturing, media buying, and route-to-market supports margins.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cencora, Inc. stack up against those of Unilever PLC.

Cencora, Inc. competitive advantage: Cencora's competitive advantage is scale in regulated healthcare distribution. Its national and international distribution footprint, provider relationships, manufacturer services, specialty logistics, and working-capital discipline create advantages that are difficult for smaller distributors to copy.

Unilever PLC competitive advantage: Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.

Future prospects matter as much as current results. The growth strategies below explain how Cencora, Inc. and Unilever PLC each plan to expand from here.

Cencora, Inc. growth strategy: Cencora's strategy is to protect core U.S. distribution scale while expanding specialty, international healthcare solutions, biopharma commercialization, cold-chain logistics, and services that are more valuable to manufacturers and providers than basic wholesale movement.

Unilever PLC growth strategy: Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.

A closer look at the financial trajectory of Cencora, Inc. and Unilever PLC rounds out the comparison.

Cencora, Inc.: Cencora reported $321.333 billion in revenue for fiscal 2025, up from $293.959 billion in fiscal 2024 and $262.173 billion in fiscal 2023. Net income attributable to Cencora was $1.554 billion in fiscal 2025, illustrating the core economics of pharmaceutical distribution: enormous revenue volume, tight margins, and careful working-capital management. The leadership story also changed. The 2025 Form 10-K lists Robert P. Mauch as President and Chief Executive Officer, while Steven H. Collis appears in transition-related exhibits after retiring from the CEO role.

Unilever PLC: Unilever's 2025 reported turnover was EUR 50.5 billion on a continuing-operations basis after Ice Cream was treated as discontinued. Underlying sales growth was 3.5%, with 1.5% volume and 2.0% price growth. This profile converts EUR 50.5 billion at an estimated 2025 average EUR/USD rate of 1.0875 for USD comparison.